# RNN 2nd Gen Model Pfizer, Inc. Pharmaceutical preparations

Stock predictor AI models:
Subscribe >> Deal exit on
Dec. 14, 2020
Deal entry on
Dec. 14, 2020
0.29%Expected margin
60.67% successful of 89 deals
$ 43.74 Last close price
at 29-oct-2021


Model's trade recommendations 0.45% Return for period

-11.51% Annual return

$294.40B Market Cap

β 0.76  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 0.45%
52wk return -15.86%
52wk Range
Sortino ratio -0.91
Sharpe ratio -0.84
Norm. RMSE 1.14%
Downside risk 12.72%
Volatility 0.00%
  • 1.60 (3.05%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Pfizer, Inc. (PFE) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 10, 2014.

Market data for PFE model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for PFE.

Model is being retrained on a regular basis.

Float 5608M
P/E 10.27
Shares Outstanding 5611M
% Held by Insiders 0.05%
% Held by Institutions 66.50%
EPS (last reported FY) $4.42
EPS (last reported Q) $1.62
EPS, estimated (last reported Q) $1.66
Total revenues $81 B
Net income $22 B